EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Contract/Alliance
Eckert Ziegler's supply of Lu-177 and Ac-225 enables Nucleus Radiopharma entering a new era in cancer care Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes. Eckert Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form. Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals. Actinium-225 and Lutetium-177 are used as radioactive substances in cancer treatment, emitting alpha (Ac-225) and beta (Lu-177) particles to destroy tumor cells. While Lu-177-based drug products have been approved for different indications and show increasing global demand, dozens of clinical studies are ongoing for both radioisotopes. According to market experts, the demand for Ac-225 will significantly increase over the next decade. "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert Ziegler. “The collaboration and the growing demand for these novel radiopharmaceuticals prove the validity of our strategic investments in radioisotope production facilities.“ "The reliable supply with Ac-225 and Lu-177 is a major prerequisite to address the increasing need for radiopharmaceutical development and manufacturing,” explained Charles S. Conroy, CEO of Nucleus. “Our agreement with Eckert Ziegler will enable us to advance our programs most efficiently and to secure patient access to innovative radiotherapies.” While Eckert Ziegler has successfully established a GMP-compliant production for Lu-177 in 2023 and is steadily upscaling the capacities, the manufacturing of larger quantities of GMP-grade Ac-225 is expected to start in 2024. About Eckert Ziegler About Nucleus RadioPharma Contact Consort Partners for Nucleus RadioPharma
31.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1820379 |
End of News | EQS News Service |
|
1820379 31.01.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Einseitige Zustimmung für Eckert & Ziegler Strahlen- und Medizintechnik AG mit mehreren Buy- und keiner Sell-Einschätzung.
Ein Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG deutet auf eine Verdopplung des aktuellen Kurses von 40.54 € hin.